|
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer Clinical research trials and Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer. Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer clinical trial. Subjects frequently get the best healthcare possible for their Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
For Condition: Peritoneal Cancer,Fallopian Cancer,Ovarian Cancers
Status: Terminated
Sponsor(s): Sponsor Name Pending ,
Synopsis: The purpose of this research study is to determine the effectiveness of the drug, topotecan, given intravenously (into a vein) together with the drug gemcitabine in patients with recurrent platinum-sensitive ovarian, fallopian or primary peritoneal cancer, as well as tumors of mixed mullerian origin. Additional purposes are to determine the long term outcome and side effects of this combination treatment. Since topotecan and gemcitabine have different mechanisms of action, the combination of these 2 drugs may provide better results than either drug alone. Prior studies suggest that the combination of topotecan and gemcitabine improves the effects on the tumor and also appeared to be well tolerated.
Details:
Eligibility:
Study Type: Interventional, Treatment, Open Label, Uncontrolled, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Female
Protocol Entry Criteria: Inclusion Criteria: (patients must meet the following criteria in order to be eligible for this study) - One prior platinum-based chemotherapy regimen for the treatment of primary disease. - Patients re-challenged with the same or one component of their first regimen are still eligible. - At least 4 weeks since last surgery or radiation therapy. - Must have had a treatment-free interval of greater than 6 months following response to platinum.
Total Enrollment:
Location and Contact Information:
Study Site
Vancouver, British Columbia, V5Z 4E6
Canada
Study Site
Abington, Pennsylvania, 19001-3788
United States
Study Site
Hattiesburg, Mississippi, 39401
United States
Study Site
Toronto, Ontario, M4N 3M5
Canada
Study Site
Phoenix, Arizona, 85006
United States
Study Site
Morristown, New Jersey, 07960
United States
Study Site
Ottawa, Ontario, K1H 8L6
Canada
Study Site
Hinsdale, Illinois, 60521
United States
Study Site
Columbus, Georgia, 31902
United States
Study Site
Rochester, New York, 14620
United States
Study Site
Puyallup, Washington, 98372
United States
Study Site
Detroit, Michigan, 48202
United States
Study Site
Sunrise, Florida, 33323
United States
Study Site
Chapel Hill, North Carolina, 27599-7570
United States
Study Site
Southfield, Michigan, 48075
United States
Study Site
Calgary, , T2N 4N2
Canada
Study Site
Rockville Centre, New York, 11570
United States
Study Site
Los Gatos, California, 95032
United States
Study Site
Lansing, Michigan, 48912
United States
Study Site
Chattanooga, Tennessee, 37403
United States
Study Site
Santa Rosa, California, 95403
United States
Study Site
Washington D.C., District of Columbia, 20010
United States
Study Site
Greenville, South Carolina, 29605
United States
Study Site
St. Louis, Missouri, 63117
United States
Additional Information:
Study ID Numbers: 104864/627;
Study Start Date:
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00061308
Other Fallopian Cancer Studies:
1. Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
Related Studies:
Other Fallopian Cancer Clinical Trials
Other Mississippi Clinical Trials
Other Hattiesburg Clinical Trials
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
|
|
|
|
|
|
|
|